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Cardiovascular disease (CVD) is the leading cause of mortality in New Zealand (NZ). Mortality rates are 
higher within the indigenous – or Māori – 
population,1 and CVD occurs about a decade 
earlier in life in Māori compared with the 
non-Māori population. For example, 45% of 
coronary artery heart disease (CAD) deaths in 
Māori occur before 65 years of age, compared 
with 11% for non-Māori.2 The relative risk of 
coronary events between 45 and 64 years is 
4.39 (95%CI 3.81-5.06) for females, and 3.01 
(95%CI 2.77-3.28) for males. Similarly, heart 
failure mortality rates are higher in younger 
Māori (45–64 years): compared to non-Māori 
the relative risk of developing heart failure 
was 4.8 (95%CI 1.44-15.93) for females 
and 10.4 (95%CI 3.52-28.61) for males. In 
older (>64 years) Māori: the relative risk of 
developing heart failure was 2.3 (95%CI 1.75-
3.03) for females and 1.89 (95%CI 1.30-1.76) 
for males. Age and gender standardised 
stroke incidence is also higher for Māori vs 
non-Māori.2 Like CAD, stroke also occurs at 
a lower age, with a mean age of 62 years for 
Māori versus 75 years for non-Māori.3
Stroke and CAD share risk factors, including 
smoking, hypertension and type 2 diabetes 
mellitus (T2DM), which are also significantly 
higher in Māori compared to non-Māori, as 
are obstructive sleep apnoea and proteinuric 
renal disease4,5 – also linked to CVD. 
Recognised hypertension is more prevalent 
in Māori men (43% versus 27% in NZ-
European men) and in women (31% versus 
18%) and perhaps more striking is the rate of 
undetected hypertension (9% for Māori men 
compared with 3% for NZ-European men, 
and 5% for Māori women compared with 1% 
for NZ-European women).6 Hypertension and 
T2DM often coexist, and the prevalence of 
T2DM in Māori is reported at 2.8 times greater 
than in the NZ-European population.7
Echocardiography provides a non-invasive 
way to assess the end-organ involvement of 
cardiac structural and functional changes, 
such as left ventricular hypertrophy (LVH), 
associated with hypertension and diabetes. 
However, echocardiography is typically only 
available to symptomatic patients and, in NZ, 
it is usually performed within the hospital 
system through physician referral. General 
practice access to echocardiography is limited 
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Abstract
Objectives: Cardiovascular disease (CVD) is the leading cause of mortality in New Zealand with 
a disproportionate burden of disease in the Māori population. The Hauora Manawa Project 
investigated the prevalence of cardiovascular risk factors and CVD in randomly selected Māori 
and non-Māori participants. This paper reports the prevalence of structural changes in the heart.
Methods: A total of 252 rural Māori, 243 urban Māori; and 256 urban non-Māori underwent 
echocardiography to assess cardiac structure and function. Multivariable logistic regression 
was used to determine variables associated with heart size.
Results: Left ventricular (LV) mass measurements were largest in the rural Māori cohort 
(183.5,sd 61.4), intermediate in the urban Māori cohort (169.7,sd 57.1) and smallest in the non-
Māori cohort (152.6,sd 46.7; p<0.001). Similar patterns were observed for other measurements 
and indexation had no impact. One-third (32.3%) met the gender-based ASE criteria for LV 
hypertrophy (LVH) with higher prevalence in both Maori cohorts (highest in the rural cohort). 
There were three significant predictors of LVH: rural Māori (p=0.0001); age (p<0.0001); and 
gender (p=0.0048). 
Conclusion: Structural and functional heart abnormalities are more prevalent in Māori 
compared to non-Māori, and especially rural Māori. Early identification should lead to better 
management, ultimately improving life expectancy and quality of life.
Key words: Māori, cardiovascular disease, echocardiography, rural, indigenous
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in NZ, and usually only for specific purposes, 
such as evaluation of heart murmurs.
Historically, it has been difficult to offer 
echocardiography in smaller centres, in part 
due to the size and relative immobility of 
imaging systems, but the advent of laptop-
sized machines now allows echocardiography 
to be applied in remote locations. Therefore, 
if there were proven benefits of wider 
application of echocardiography to new 
populations and potentially asymptomatic 
high-risk populations, this would now be 
entirely feasible and potentially cost- and life-
saving in the long-term. We have previously 
reported higher CVD risk in both Māori 
cohorts of this study compared to the non-
Māori cohort, with the highest risk observed 
in the rural Māori cohort,8 and that treatment 
may be suboptimal. We hypothesise that 
LVH prevalence may also be higher in the 
Māori community with a similar difference 
between the rural and urban cohorts, partly 
reflective of differing access to healthcare 
services. Thus, as part of a wider study of 
cardiovascular risk factors in Māori, the aim of 
this study was to determine the prevalence of 
LVH in a remote, rural, predominantly Māori 
community and compare this with an urban 
Māori community and an urban non-Māori 
community. 
Methods
The Hauora Manawa Project, or The 
Community Heart Study, was established to 
gather prevalence data for cardiovascular 
risk factors and established cardiovascular 
disease within randomly selected samples 
from two different Māori Communities (Ngati 
Kahungunu ki Wairoa in rural Hawkes Bay and 
Ngai Tahu ki Waitaha in urban Christchurch) 
and a non-Māori urban Christchurch cohort, 
to identify objective markers to guide 
monitoring of cardiovascular disease risk 
(as determined by the NZ cardiovascular 
guidelines)9 and to follow and document 
the implementation and outcomes of 
interventions for study participants.10 This 
was a population-based study that used 
a Kaupapa Māori approach (a conceptual 
framework that places Māori values, beliefs 
and experiences at the centre of the research 
process and locates resultant data within that 
social context)11 with participants randomly 
selected from the electoral rolls (electoral 
roll registration is mandatory in NZ). A 
simple random sample was used without 
replacement from each stratum, specifying 
the number to be selected. Full details of 
sample selection are published elsewhere.10 
The roll was stratified by age (20–29; 30–39; 
40–49; 50–64) and by gender. For both Māori 
cohorts, everyone in the age range 20–64 
years had an equal probability of selection. 
However, the Christchurch non-Māori cohort 
was frequency matched to the age- and 
gender-group distribution of the Christchurch 
Māori descent sample. The overall study 
methods (including selection) have been 
previously documented.8,10 Briefly, all 
participants who provided informed consent 
completed a series of health and societal 
questionnaires, had blood samples taken 
and had body height and weight measured 
and body mass index (BMI) calculated. Body 
composition was assessed by bioimpedance 
using the Tanita Body Composition 
Analyzer, TBF 310 (Tanita Inc, Tokyo, Japan). 
Participants were examined by a cardiologist 
or physician and underwent cardiovascular 
risk assessment, an electrocardiograph and 
an echocardiogram. Blood pressure was 
measured while seated on two occasions at 
least 20 minutes apart. Any abnormalities or 
new conditions that were detected triggered 
referral to either a local general practitioner 
or local hospital for specialist care, as clinically 
indicated and appropriate. Ethics approval 
was gained from the Multi-Region Ethics 
Committee (MEC/06/03/026).
Echocardiography methods
A standard protocol was developed that 
included two dimensional, m-mode and 
Doppler images obtained in the parasternal 
long and short axis, the apical four, five and 
two chamber views, and subcostally when 
required. A brief screening scan that included 
anatomical and functional parameters 
as described below was undertaken 
(including subjective assessment of all 
chamber size and valve function). Suspected 
abnormalities were not interrogated fully at 
the research clinic, but instead referred for 
full echocardiography at a later date. There 
were two exceptions where we referred 
the participants immediately to the local 
cardiology service: one participant with a 
previously undiagnosed left atrial myxoma 
and another with significant regional wall 
motion abnormalities who was experiencing 
angina during the echo examination. 
Most of the echocardiograms were 
performed using one of two machines: 
Sonosite MicroMaxx or Sonosite MTurbo 
with a broadband 1-5 MHz phased array 
transducer. On two occasions, for logistical 
reasons, we used an Acuson Cypress and 
a Philips CX50. A team of experienced 
sonographers (see acknowledgements) 
performed the echocardiography and initial 
measurements. The images were immediately 
reviewed, and over-measured when needed 
by a single observer (GW). All images were 
digitally stored and retained for future 
review if required. Each screening echo was 
performed in about 10 minutes.
The following measurements were obtained: 
1) m-mode measurements: left ventricular 
end-diastolic dimension (LVEDD), left 
ventricular end-systolic dimension (LVESD), 
interventricular septal thickness (IVS), 
posterior left ventricular wall thickness 
(PW), left atrial diameter (LAD), and aortic 
root diameter (AoD); 2) two-dimensional 
measurements: left atrial area (LAA) obtained 
from the apical four chamber view; 3) 
Doppler mitral early to late filling velocity 
ratio (E:A), and peak aortic velocity; mitral 
early to late filling velocity ratio (E:A); and 4) 
tissue Doppler medial mitral annular early 
diastolic descent velocity (Ea). From these 
measurements, the following were calculated: 
left ventricular (LV) mass using the ASE 
recommended m-mode method;12 fractional 
shortening (FS) and ejection fraction (LVEF). 
The ratio or E:Ea was also calculated and 
mitral filling pattern derived from the 
combination of these measurements. We 
used ASE gender-based references values to 
determine the presence (or absence) of LVH 
based on LV mass index.12
Statistical analysis
Analyses were carried out in SAS 9.1. Analysis 
of variance (ANOVA) was used to compare the 
differences between the three cohorts (rural 
Māori, urban Māori and urban non-Māori) on 
quantitative variables. Logistic regression was 
used to determine the contributors to LVH, 
and the following variables were included: 
urban Māori, rural Maori, age, gender and 
estimated Framingham CVD risk, which 
incorporates other conventional risk factors 
(e.g. T2DM, hypertension, smoking). Both 
Māori cohorts were compared to the urban 
non-Māori cohort.
Results
We have previously reported the CVD risk 
profiles of these cohorts8 that include 252 
rural Māori participants, 243 urban Māori 
participants and 256 urban non-Māori 
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participants and demonstrated elevated 
blood pressure, hyperlipidaemia, higher 
rates of obesity and smoking particularly in 
rural Maori. Briefly, the mean age in the rural 
Māori was higher (45.7 years) than both of the 
other groups (42.6 for the urban Māori cohort 
and 43.6 for the non-Māori group) (Table 1). 
Gradual increases in systolic blood pressure 
were observed, with the highest values in 
the rural Māori cohort and the lowest in the 
non-Māori cohort, although this was less 
pronounced for diastolic blood pressure. 
Height, weight and measures of obesity 
(BMI, BSA) indicate that obesity may be more 
prevalent in the rural Māori cohort than the 
urban Māori or non-Māori cohorts, but fat-
free mass was not different across the groups. 
Measures of T2DM (fasting blood glucose, 
HbA1c and insulin) were highest in the rural 
Māori, followed by urban Māori and lowest 
in the non-Māori cohort. Similarly, the rates 
of previously diagnosed and newly detected 
elevated blood markers of diabetes were 
highest in the rural Māori, followed by urban 
Māori and lowest in the non-Māori cohort.
Echocardiographic measurements
The structural measurements of the heart 
suggest that the rural Māori cohort had the 
largest hearts and the urban non-Māori 
cohort the smallest hearts (Table 2). The left 
ventricular diastolic dimension was highest 
in the rural Māori cohort, smallest in the non-
Māori cohort, and intermediate in the urban 
Māori cohort. No differences were detected 
in the systolic dimensions. Other measures 
of heart size (left atrial diameter, aortic 
root diameter and left atrial area) showed 
similar trends. This was also apparent for left 
ventricular wall thickness and calculated 
mean LVM (183.5 [SD 61.4] versus 169.7 [SD 
57.1] versus 152.6 [SD 46.7] p<0.001). In order 
to account for body size, LVM was indexed 
to either BSA, height or fat-free mass. The 
differences persisted: LVM was consistently 
highest in the rural Māori cohort and 
consistently lowest in the non-Māori cohort. 
Using the ASE recommended cut points of 
LVH, 238 of the 737 participants (32.3%) in 
whom LVM was available met the gender-
based criteria for LVH. The prevalence of LVH 
was higher in both Māori cohorts and highest 
in the rural Māori cohort. The prevalence also 
increased with age and, with the exception 
of the youngest age band, this was true for 
all of the groups (Figure 1). Across all but the 
youngest age band, more participants in the 
two Māori cohorts met the ASE LVH criteria 
Table 1: Baseline demographics and clinical measurements.
Rural Māori 
Mean (sd) 
N=252
Urban Māori 
Mean (sd) 
N=243
Urban Non-Māori 
Mean (sd) 
N=256
ANOVA or 
*Chi-Square
Age, years 45.7 (11.5) 42.6 (11.2) 43.6 (11.5) 0.00908
Gender, male 102 (40.5%) 110 (45.3%) 125 (91.9%) 0.166
Systolic BP, mmHg 130.1 (20.1) 128.3 (20.6) 124.5 (14.8) 0.00264
Diastolic BP, mmHg 85.3 (11.1) 86.2 (13.6) 83.1 (12.1) 0.01821
Height, m 168.4 (8.6) 169.2 (9.1) 170.6(9.3) 0.02868
Weight, kg 87.2 (21.9) 83.6 (20.0) 76.0 (15.0) <0.001
Body Mass Index, kg/m2 30.7 (7.3) 29.1 (6.4) 26.1 (4.5) <0.001
Fat Free Mass, kg 55.2 (11.2) 55.8 (12.3) 53.8 (10.55) 0.11414
Body surface area, m2 1.96 (0.24) 1.93 (0.23) 1.87 (0.21) <0.001
Fasting blood glucose, mmol/L 5.8 (1.66) 5.4 (0.91) 5.3 (0.54) <0.001
HBA1c 6.3 (1.43) 5.4 (0.85) 5.2 (0.56) <0.001
Plasma insulin, pmol/L 71.6 (64.8) 52.4 (54.3) 42.4 (34.27) <0.001
Creatinine,  umol/L 79.7 (50.7) 81.7 (18.4) 81.8 (12.5) 0.71684
eGFR,  ml/min/1.73m2 85.6 (22.5) 84.1 (13.0) 83.9(13.3) 0.459
Co-morbidities:
Prior hypertension, n (%) 40 (16 %) 36 (15 %) 26 (10 %) <0.001
Newly identified hypertension,  (%) 56 (22 %) 57 (24 %) 45 (18 %) 0.235
Prior dyslipidaemia, n (%) 40 (16 %) 17 (7.1 %) 7 (3 %) 0.1407
Newly identified dyslipidaemia, n (%) 107 (43 %) 134 (55 %) 108 (42 %) 0.008
Type 2 diabetes, n (%) 29 (3.9 %) 11 (1.5 %) 7 (0.93 %) <0.001
New detection of fasting blood glucose or 
HBA1c  n (%)
64 (29.4%) 22 (9.5%) 16 (6.5%) <0.001
Table 2: Baseline echocardiographic measurements.
 Rural Māori Urban Māori Urban Non-Māori ANOVA
N Mean (sd) N Mean (sd) N Mean (sd)
Measurements of heart size
Left ventricular end-diastolic dimension, mm 250 52.8 (6.0) 238 52.4 (5.7) 255 51.4 (5.22) 0.03
Left ventricular end-systolic dimension, mm 243 32.1 (5.0) 238 31.63 (5.7) 252 31.2 (4.9) 0.11
Interventricular septal thickness, mm 247 9.3 (1.78) 239 8.96 (1.94) 255 8.49 (1.81) <0.001
Posterior wall thickness, mm 247 9.2 (1.87) 238 8.61 (1.87) 255 8.14 (1.72) <0.001
Left atrial dimension, mm 239 37.8 (6.1) 235 37.3 (5.4) 253 36.4 (5.5) 0.02
Left atrial dimension index, mm/m2 239 19.4 (2.9) 235 19.4 (2.5) 253 19.5 (2.8) 0.78
Aortic root dimension, mm 218 34.0 (4.8) 235 32.6 (4.8) 253 30.9 (4.9) <0.001
Aortic root dimension, mm/m2 218 17.4 (2.5) 235 14.7 (2.3) 253 16.5 (2.3) <0.001
Left atrial area, cm2 239 21.6 (5.2) 234 21.4 (4.8) 248 20.7 (4.2) 0.08
Systolic function measurements
Left ventricular fractional shortening, % 235 39.1 (6.0) 230 39.8 (6.4) 247 39.9 (6.5) 0.33
Left ventricular ejection fraction, % 168 67.7 (8.6) 224 68.8 (9.3) 243 69.6 (8.0) 0.10
Diastolic function measurements
Mitral valve E velocity, cm/s 250 67.0 (17.2) 240 71.6 (16.0) 256 76.3 (17.1) <0.001
Mitral valve A velocity, cm/s 246 61.0 (17.1) 238 56.8 (17.4) 255 56.0 (15.2) 0.002
E:A 246 1.17 (0.42) 238 1.36 (0.49) 255 1.5 (0.83) <0.001
Mitral annular E velocity, cm/s 248 8.51 (2.62) 238 10 (2.80) 251 10.5 (2.66) <0.001
Mitral E:Annular E velocity, 243 8.24 (2.39) 235 7.57 (2.64) 251 7.54 (2.23) 0.002
Calculation of left ventricular mass
Left ventricular mass, g 247 183.5 (61.4) 236 169.7 (57.1) 255 152.6 (46.7) <0.001
Left ventricular mass/body surface area, g/m2 246 92.7 (24.8) 236 87.1 (23.8) 255 80.8 (20.4) <0.001
Left ventricular mass/height, g/m 246 108.6 (34.6) 236 99.8 (31.4) 255 89.0 (25.2) <0.001
Left ventricular mass/fat free mass, g/kg 240 3.31 (0.81) 232 3.05 (0.76) 254 2.84 (0.66) <0.001
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and, further to this, LVH detection was highest 
in the rural Māori cohorts in all age bands. 
Similarly, LVH prevalence fell intermediate 
to the others in the urban Māori cohort 
(Table 3). In logistic regression with multiple 
predictors, the only independent predictors 
of LVH were being in the rural Māori cohort 
(p=0.0001), age (p<0.0001) and gender 
(p=0.0048). Being in the urban Māori cohort 
did not reach significance (p=0.075), nor did 
the 5-year CVD risk score (0.084) (Table 4). 
This analysis was repeated with BMI in the 
model and, although BMI was an important 
and significant contributor to the model, the 
contributions and significance of the other 
variables was not affected. 
With regard to cardiac function, measures 
of systolic function were similar across all 
three groups, although diastolic parameters 
consistently showing that rural Māori have 
the worst diastolic filling profile: E:A 1.17 (SD 
0.42) versus 1.36 (SD 0.49) for urban Māori 
and 1.50 (0.83) for urban non-Māori, p<0.001; 
and the highest E:Ea (8.2 (SD 2.4) versus 7.6 
(SD 2.6) for urban Māori and 7.54 (2.23) for 
urban non-Māori, p=0.002. (Table 2). Regional 
wall motion abnormalities were observed 
in 51 participants, of which 31 included 
more than one wall segment. These were 
less frequently seen in the urban non-Māori 
cohort (2/31) than the urban Māori cohort 
(6/31) and the rural Māori cohort (13/31); 
however, single wall motion abnormalities 
were more frequently observed in the urban 
non-Māori and rural Māori cohorts (12/31 in 
both) compared to the urban Māori cohort 
(6/31). A history of rheumatic fever was 
reported most frequently in the rural Māori 
cohort (24/252) and the urban Māori cohort 
(10/243) and least in the urban non-Māori 
cohort (2/256). Overall, there were only three 
cases of significant valve disease: one with a 
prosthetic valve and two with mild-moderate 
mitral valve disease. No significant valve 
disease was detected.
Discussion
This study has highlighted the higher 
prevalence of structural heart abnormalities 
in Māori participants, especially those who 
live in a rural setting. This is the first study 
of its kind to perform population-based 
screening with echocardiography in NZ, and 
it has revealed some interesting findings 
that could have important implications for 
the management and prevention of CVD, 
especially in NZ Māori, and potentially in any 
remote high-risk population. 
For many years, it has been known that the 
rate of CVD is higher in Māori and that CVD 
presents earlier in Māori.2 The larger study, of 
which this is a sub-analysis, was designed to 
investigate the spectrum of possible reasons 
why this may occur. In the first publication 
from this population-based study, we have 
reported that obesity, smoking, hypertension, 
dyslipidaemia, T2DM, and calculated CVD risk 
are higher in rural versus urban Māori and 
higher than the non-Maori cohort.8 
This paper adds to that work by 
demonstrating a higher prevalence of 
structural heart abnormalities in the rural 
and urban Māori cohorts than in the non-
Maori cohort. A key finding of this study was 
the significantly higher left ventricular wall 
thickness, resulting in higher LVM across the 
groups (rural Māori having the highest values 
and non-Māori the lowest) and reflected in 
the prevalence of LVH data as well. Overall, 
the prevalence of LVH in the study was 
about one-third; however, this is not evenly 
distributed among the three cohorts. Rural 
Māori have the highest rates of LVH: 75% 
in those aged 60–69 years; 54% in those 
aged 40–49 years; and about 40% in those 
aged 40–49 years. But, between 40 and 60 
years, both Māori cohorts had much higher 
incidence of LVH than the non-Maori cohort. 
These differences persisted after indexation 
of LVM to any measure of body size.
The reasons for the high prevalence of 
LVH in these communities are likely to be 
multifaceted. We have already demonstrated 
higher calculated CVD risk in these cohorts 
and suboptimal treatment according to CVD 
guidelines.8 Undoubtedly, co-morbidity such 
as hypertension and T2DM play a role, since 
both are precursors for the development 
of LVH. The rural and urban Māori cohorts 
in this study had a prevalence of T2DM of 
around 11% and diagnosed hypertension 
of about 25%,8 but we did identify further 
cases of undiagnosed hypertension in the 
rural Māori cohort (22%), the urban Māori 
cohort (24%) and the urban non-Māori cohort 
(18%).8 Lastly, even when body size was taken 
into account, LVH was linked to obesity (as 
measured by BMI) in these cohorts. The high 
rates of LVH may reflect this disease burden, 
but it may also represent poor management 
of disease. 
Worldwide, there are differences in the 
prevalence of many health-related conditions, 
Figure 1: ASE defined LVH by age and cohort. Table 3: Prevalence of ASE-defined LVH .
Age Band years Rural Māori 
%LVH  
(95% CI lower, upper)
Urban Māori 
%LVH  
(95% CI lower, upper)
Urban non-Māori 
%LVH  
(95% CI lower, upper)
20-29 13.0 (2.80–31.0) 27.8 (14.0–45.0) 20.0 (8.4–37.0)
30-39 30.9 (19.0–45.0) 20.0 (11.0–32.0) 5.7 (1.6–14.0)
40-49 39.7 (28.0–53.0) 39.7 (28.0–52.0) 16.4 (8.8–27.0)
50-59 54.3 (42.0–66.0) 48.8 (33.0–65.0) 30.8 (19.0–45.0)
60-69 75.0 (55.0–89.0) 52.4 (31.0–74.0) 44.0 (25.0–63.0)
Overall, N (%) 105 (42.7%) 83 (35.2%) 50 (19.6%)
Table 4: Multivariable logistic regression predictors of LVH (LVM/BSA cut point by gender).
Model parameter Odds Ratio 95%CI P value
Urban Māoria 1.91 1.29, 2.84 0.74
Rural Māoria 3.26 2.22, 4.80 <0.001
Age, per year 1.03 1.02. 1.05 <0.001
Gender, male 0.76 0.55, 1.04 <0.08
5 year CVD Risk > 15% 1.78 1.08, 2.9 0.02
a:  Relative to reference group of urban non-Maori
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although not consistently in one direction. 
The reasons for disparity when they exist 
are complex, but include individual and 
community action, health system and 
government policies.13 This is confounded 
in countries such as Australia and NZ, 
where the indigenous people comprise a 
higher proportion of rural inhabitants and 
the impacts of colonisation are reflected in 
economic disadvantage.14
Recently, using geographical information 
systems, it has been shown that the distance 
is a barrier to both having blood pressure 
measured and to visiting a GP or filling a 
prescription.15 This is particularly relevant 
in rural NZ, which is typically quite sparsely 
populated. In addition, these areas are also 
often the most economically deprived. 
There are significant challenges facing the 
future of general practice and access to 
rural general practice is a priority for NZ.16 
Any improvements in this service provision 
should alleviate some of the differences 
observed in this study. However, there is also 
a disparity among NZ’s regional hospitals in 
terms of cardiovascular services. For example, 
patients who present at smaller regional 
centres are less likely to receive effective 
treatment for acute coronary syndromes in 
a timely manner,17 and we know that there 
are geographical differences in the provision 
of echocardiography throughout NZ with 
some of the most remote areas performing 
the least number of echocardiograms.18 
Yet echocardiography is an excellent way 
to assess LVH and to quantify LVM. Left 
ventricular hypertrophy is a modifiable CVD 
risk factor – most modern antihypertensive 
treatments have been shown to decrease 
LVM19 – and so the detection of LVH should be 
a priority in high-risk patient groups. 
The definition of LVH by echocardiography 
requires reliable normal reference ranges. 
One of the challenges is how to define 
normal limits for individuals of different 
size and the ASE recommend indexation to 
account for body size.12 Historically, this has 
meant dividing the LVM by body surface 
area, the so-called LVM index (LVMI). The 
challenge with using BSA as the indexation 
variable is that it forgives LVH in obese 
individuals and, conversely, over-estimates 
LVH in thin individuals.20 More recently, it 
has been suggested that height be used as 
the indexation variable of choice,21 which 
alleviates the under detection in obesity, 
but as height does not change over time 
the impact of increased weight is not taken 
into account. It has been demonstrated that 
the most significant determinant of LVM is 
fat-free mass22,23 since it takes into account 
metabolically active soft tissue, and not the 
rather inert fat mass. Unfortunately, reference 
ranges for LVM indexed to fat-free mass do 
not exist. 
It is entirely feasible that using the ASE LVM 
thresholds in this study has resulted in an 
‘over definition’ of LVH and that if fat-free mass 
reference ranges were available then LVH 
prevalence would drop significantly because 
fat-free mass is ethnic-dependent.24,25 Māori 
have higher fat-free mass for a given weight 
compared to European cohorts.25 However, 
if the differences observed in this study were 
related to over-diagnosing LVH on this basis, 
then the LVM indexed to fat-free mass would 
be the same in all three groups, but it is not. 
Similarly, the indexed LVM would be the same 
for both Māori groups if this was related to 
ethnicity and body composition alone. The 
gradual increase observed in unindexed 
LVM – highest in rural Māori, lowest in urban 
non-Māori, intermediate in urban Māori – 
persisted despite any indexation method, 
suggesting that a real difference in LVH may 
be present. The addition of a rural non-Māori 
cohort, which we did not have, may have 
added extra clarification in this regard.
Further support for a pathological difference 
in LVH may be garnered from the other 
echocardiographic data showing a worse 
diastolic profile that is aligned with increased 
prevalence of LVH, and this is more evident 
in the Māori and rural Māori participants in 
particular. In a recent systematic review, we 
have shown geographic (and thus ethnic) 
differences in LVM,26 indicating that there is 
a need for ethnic-specific reference ranges 
of echocardiography. But, even if there were 
Māori reference ranges available, it is unlikely 
that the use of these would eliminate the 
LVH altogether. It is interesting to note that 
in the multivariable predictors of LVH, age 
and gender were important predictors, as 
was being in the rural Māori group. Neither 
CVD risk, nor being in the urban Māori group, 
quite reached significance in the model. This 
suggests the LVH observed in this study is 
not simply related to ethnicity, nor is it just 
a marker of worse CVD risk, and it may offer 
additional information beyond the usual 
screening parameters.
Does this study support population-based 
echocardiographic screening in the Māori 
community? For a screening program to be 
effective there needs to be a readily available 
test and readily available treatment. In this 
case, the test is echocardiography, which 
has the potential to be applied widely. Other 
tests, such as electrocardiography (ECG), are 
poor markers of LVH. In a cohort of patients 
with T2DM, we recently demonstrated 
the superiority of echocardiography over 
ECG – 60% of patients with T2DM had 
echo-defined LVH versus virtually none 
with ECG27 – providing a good rationale for 
echocardiographic screening patients with 
T2DM with echocardiography, partly in order 
detect any other evidence of CAD. Therefore, 
it would be reasonable to suggest that all 
adult Māori undergo an echocardiogram, 
especially given we have already reported 
that CVD risk (including hypertension) 
is elevated and often unnoticed and 
undertreated.8 However, when to start such a 
screening program and how often to repeat 
the test cannot be addressed from the current 
data, and such a screening program would be 
expensive to implement.
In terms of treatment, regression of 
LVH is achieved through management 
of hypertension – most of the modern 
antihypertensive agents have been shown 
to regress LVH in clinical trials.19 As previously 
discussed, the degree of hypertension was 
underestimated in the three cohorts prior 
to the study, so improved hypertension 
identification, monitoring and treatment 
should be the first step, and the role of 
24-hour ambulatory blood pressure could 
be explored in this cohort. The addition of 
echocardiography to detect LVH may or 
may not be useful if the management of 
hypertension is improved. Furthermore, 
if obesity were able to be reduced, it is 
conceivable that there may be a favourable 
impact on LVH as well. 
The increasing availability of hand-carried 
ultrasound could make screening for LVH 
more widely accessible. But there are barriers 
to overcome, such as who would provide this 
service and how many hand-carried devices 
would be required. For example, the NZ 
healthcare system is largely a public-funded 
system where echocardiography is performed 
in association with a hospital. There is already 
significant variation (3-4 fold difference) in the 
delivery and number of scans performed per 
population served through each hospital.18 
The system is already stretched in terms 
of equipment and manpower, and this is 
especially true in rural areas. Any additional 
screening would have to fall outside of the 
current service. Despite the challenges that 
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implementing a screening program would 
create, the imbalance and burden of disease 
identified through this research has been 
apparent and troubling for some time. 
Although there is no technical reason why 
hand-carried ultrasound may underperform 
in this setting, there are challenges with 
imaging patients with larger chests. We have 
compared cardiology-fellow performed 
echocardiography with expert sonographer 
measurements obtained with a full cart 
system and found that, for detection of LVH, 
the sensitivity was 75%, specificity 94%, 
positive predictive value 79% and negative 
predictive value was 93% (unpublished data) 
in a separate cohort of patients with type 
2 diabetes.27 In the current study, expert 
sonographers collected and measured all of 
the images, so image quality is unlikely to 
have affected our results.
Conclusion
In this study, structural and functional 
changes in the heart were present at higher 
rates in Māori and especially rural Māori, 
compared to an urban non-Māori population. 
This data supports the importance of our 
previous report of high CVD risk and under 
diagnosis and under treatment in Māori and 
especially rural Māori, and is consistent with 
other studies that consistently demonstrate 
disparities in CVD disease prevalence, age 
of CVD onset, confluence of risk factors 
(including smoking, T2DM and hypertension) 
and access to health care services. 
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